



## Klinik für Urologie: Erfasste Publikationen aus 2024

ID: 542915

MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer. **Abdom Radiol (NY)** 2024; 49(1): 192-201; Impact Factor=2.2; Impact Factor 2024=2.2; Typ=Journal Article;

Boschheidgen M, Schimmöller L, Kastl R, Drewes LR, Jannusch K, Radke KL, Kirchner J, Ullrich T, **Niegisch G**, **Albers P**, Antoch G, **Radtke JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 556707

Bladder preservation in adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse radical cystectomy

**Aktuelle Urol** 2024; 55(01): 24-25; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=Rexer H, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571138

Retroperitoneal Residual Tumor Resection after Chemotherapy of malignant Testicular Tumors

**Aktuelle Urol** 2024; 55(05): 467-476; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=**Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571313

[Histopathological analysis of germ cell tumours: aspects to consider].

**Aktuelle Urol** 2024; 55(6): 528-536; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=Journal Article;Review;English Abstract;

Fichtner A, **Nettersheim D**, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 539773

[Neutropenia - when is GCSF support indicated?].

**Aktuelle Urol** 2024; 55(1): 38-43; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=English Abstract;Journal Article;

**Rehlinghaus M**, **Rehker P**, **Che Y**, **Grunewald CM**, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602126

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

**Ann Oncol** 2024; 35(1): 107-117; Impact Factor=65.4; Impact Factor 2024=65.4; Typ=Randomized Controlled Trial;Clinical Trial, Phase III;Journal Article;

Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y, **THOR cohort 2 investigators**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 575097

A challenging discrimination of an intensely [18F]PSMA-1007-avid solitary lesion at the skull base in a

patient with biochemical recurrence of prostate cancer.

**BJR Case Rep** 2024; 10(6): ; Impact Factor=0.5; Impact Factor 2024=0.5; Typ=Case Reports;Journal Article;

Novruzov E, **Niegisch G**, Pauck D, Schmitt D, Kuhlmann J, Beseoglu K, Antoch G, Schimmöller L, Giesel FL, Mamlins E

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571014

Mortality from prostate cancer in the years 2007-2021 in North Rhine-Westphalia, Germany.

**BMC Urol** 2024; 24(1): ; Impact Factor=1.9; Impact Factor 2024=1.9; Typ=Journal Article;

Claaßen K, Karpinski M, Kajüter H, Hüsing J, Möller L, Wellmann I, Grünwald V, Hadaschik B, **Albers P**, Stang A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 570106

[Prostate cancer screening? Only evidence-based, risk-adjusted, and organized!].

**Bundesgesundheitsblatt Gesundheitsforschung, Gesundheitsschutz** 2024; 67(9): 1047-1053;

Impact Factor=1.5; Impact Factor 2024=1.5; Typ=English Abstract;Journal Article;Review;

**Albers P**, Becker N

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 565608

Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.

**Cancer Lett** 2024; 585(): ; Impact Factor=10.1; Impact Factor 2024=10.1; Typ=Journal Article;

**Pongratanakul P**, Bremmer F, Pauls S, Poschmann G, Kresbach C, **Parmaksiz F**, **Skowron MA**, Fuß J, **Stephan A**, Paffenholz P, Stühler K, Schüller U, Ströbel P, Heidenreich A, **Che Y**, **Albers P**, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571980

Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

**Cancers (Basel)** 2024; 16(17): ; Impact Factor=4.4; Impact Factor 2024=4.4; Typ=Journal Article;

Hilser T, Darr C, **Niegisch G**, Schnabel MJ, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Niedersüß-Beke D, Grünwald V

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564414

Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2.

**Cell Death Discov** 2024; 10(1): ; Impact Factor=7.0; Impact Factor 2024=7.0; Typ=Journal Article;

Schmitt L, Lechtenberg I, Drießen D, Flores-Romero H, **Skowron MA**, Sekeres M, Hoppe J, Krings KS, Llewellyn TR, Peter C, Stork B, Qin N, Bhatia S, **Nettersheim D**, Fritz G, García-Sáez AJ, Müller TJJ, Wesselborg S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 555128

Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.

**Clin Cancer Res** 2024; 30(2): 404-412; Impact Factor=10.2; Impact Factor 2024=10.2; Typ=Journal Article;Research Support, Non-U.S. Gov't;

Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, **Che Y**, **Hiester A**, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzlbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 572008

Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

**Clin Genitourin Cancer** 2024; 22(5): ; Impact Factor=2.7; Impact Factor 2024=2.7; Typ=Journal Article;Multicenter Study;

Viktor G, Martin B, Mohammad-Reza R, **Günter N**, Marco S, Anne F, Michael M, Christoph M, Mark-Oliver Z, Anke W, Andreas H, Jochen C, C D, Thomas H, M S, Disorn S, Philipp I  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 560954

Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.

**Clin Radiol** 2024; 79(3): e468-e474; Impact Factor=1.9; Impact Factor 2024=1.9; Typ=Journal Article;

Ziayee F, Schimmöller L, Boschheidgen M, Kasproski L, **Al-Monajjed R**, Quentin M, **Radtke JP**, **Albers P**, Antoch G, Ullrich T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567868

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.

**Eur J Cancer** 2024; 202(): ; Impact Factor=7.1; Impact Factor 2024=7.1; Typ=Journal Article;

Bührer E, D'Haese D, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, **Lorch A**, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn DJ, Sternberg CN, Heidenreich A, Collette L, Gillissen S, Beyer J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564328

MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.

**Eur J Radiol** 2024; 175(): ; Impact Factor=3.3; Impact Factor 2024=3.3; Typ=Journal Article;

Quentin M, Boschheidgen M, **Radtke JP**, Spohn F, Ullrich T, Drewes L, Valentin B, **Lakes J**, **Al-Monajjed**, **Arsov C**, Esposito I, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 568797

PI-QUAL version 2: the urologist's perspective.

**Eur Radiol** 2024; 34(11): 7063-7064; Impact Factor=4.7; Impact Factor 2024=4.7;

Typ=Editorial;Comment;

Stabile A, Giannarini G, **Radtke JP**, Crestani A, **Albers P**, Briganti A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 540996

Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.

**Eur Urol** 2024; 85(2): 105-111; Impact Factor=25.2; Impact Factor 2024=25.2; Typ=Journal Article;  
Boschheidgen M, **Albers P**, Schlemmer HP, Hellms S, Bonekamp D, Sauter A, Hadaschik B, Krilaviciute A, **Radtke JP**, Seibold P, **Lakes J**, **Arsov C**, Gschwend JE, Herkommer K, Makowski M, Kuczyk MA, Wacker F, Harke N, Debus J, Körber SA, Benner A, Kristiansen G, Giesel FL, Antoch G, Kaaks R, Becker N, Schimmöller L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564329

PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.

**Eur Urol** 2024; 86(3): 240-255; Impact Factor=25.2; Impact Factor 2024=25.2; Typ=Journal Article;Practice Guideline;

Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, Baroni RH, Briganti A, De Visschere P, Dickinson L, Gómez Rivas J, Haider MA, Kesch C, Loeb S, Macura KJ, Margolis D, Mitra AM, Padhani AR, Panebianco V, Pinto PA, Ploussard G, Puech P, Purysko AS, **Radtke JP**, Rannikko A, Rastinehad A, Renard-Penna R, Sanguedolce F, Schimmöller L, Schoots IG, Shariat SF, Schieda N, Tempany CM, Turkbey B, Valerio M, Villers A, Walz J, Barrett T, Giganti F, Moore CM

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 570216

Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.

**Eur Urol** 2024; 85(3): 215-216; Impact Factor=25.2; Impact Factor 2024=25.2; Typ=Editorial;

**Albers P**, van Poppel H

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567466

Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBAST Trial.

**Eur Urol** 2024; 86(6): 493-500; Impact Factor=25.2; Impact Factor 2024=25.2; Typ=Journal Article;  
Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, **Lakes J**, **Radtke JP**, Kuczyk M, Harke NN, Debus J, Fink CA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Kristiansen G, Hadaschik B, **Arsov C**, Schimmöller L, Antoch G, Giesel FL, Makowski M, Wacker F, Schlemmer HP, Becker N, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 558893

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.

**Eur Urol** 2024; 85(2): 114-122; Impact Factor=25.2; Impact Factor 2024=25.2; Typ=Journal Article;

Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, **Albers P**, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Sethi H, Aleshin A, Shi Y, Davarpanah N, Carter C, Bellmunt J, Mariathasan S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 576213

Prostate Biopsy: The Transrectal Approach Is Safe.

**Eur Urol Focus** 2024; 10(5): 688-690; Impact Factor=5.6; Impact Factor 2024=5.6; Typ=Journal Article;

**Busshoff I**, **Haidl F**, **Radtke JP**, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 577029

Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.

**Eur Urol Focus** 2024; 10(5): 851-857; Impact Factor=5.6; Impact Factor 2024=5.6; Typ=Clinical Study;Journal Article;Multicenter Study;

Dieckmann KP, Grobelny F, Soave A, **Che Y**, Nestler T, Matthies C, Heinzlbecker J, Winter A, Heidenreich A, Niemzok T, Dumlupinar C, Angerer M, Wülfing C, Paffenholz P, Belge G  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 558875

Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.

**Eur. Urol. Open Sci.** 2024; 59(): 30-38; Impact Factor=4.5; Impact Factor 2024=4.5; Typ=Journal Article;

Valentin B, **Arsov C**, Ullrich T, **Al-Monajjed R**, Boschheidgen M, Hadaschik BA, Giganti F, **Giessing M**, Lopez-Cotarelo C, Esposito I, Antoch G, **Albers P**, **Radtke JP**, Schimmöller L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569019

RAISN: Robot-assisted Indocyanine Green-guided Sentinel Node Biopsy in Clinical Stage I Germ Cell Tumor

**Eur. Urol. Open Sci.** 2024; 66(): 55-59; Impact Factor=4.5; Impact Factor 2024=4.5; Typ=Article; **Vermeulen-Spohn MS**, **Pongratanakul P**, **Thy S**, Dukart J, **Albers P**, **Che Y**

Medline-ID fehlt, Web of Science-ID (ISI-LOC) vorhanden

ID: 568513

Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.

**Exp Cell Res** 2024; 439(1): ; Impact Factor=3.5; Impact Factor 2024=3.5; Typ=Journal Article;

**Müller MR**, **Burmeister A**, **Skowron MA**, **Stephan A**, **Söhngen C**, Wollnitzke P, Petzsch P, Alves Avelar LA, Kurz T, Köhrer K, Levkau B, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564930

Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.

**Front Immunol** 2024; 15(): ; Impact Factor=5.9; Impact Factor 2024=5.9; Typ=Journal Article;Research Support, Non-U.S. Gov't;

Li Y, Sharma A, **Hoffmann MJ**, Skowasch D, Essler M, Weiher H, Schmidt-Wolf IGH

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 566901

Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.

**Future Oncol** 2024; 20(19): 1351-1366; Impact Factor=2.6; Impact Factor 2024=2.6; Typ=Journal Article;

**Niegisch G**, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 568261

Value-Based Health Care for Prostate Cancer Centers by Implementing Specific Key Performance Indicators Using a Balanced Score Card.

**Healthcare (Basel)** 2024; 12(10): ; Impact Factor=2.7; Impact Factor 2024=2.7; Typ=Journal Article;

**Radtke JP, Albers P**, Hadaschik BA, Graefen M, Meyer CP, Behr B, Nüesch S  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 568793

Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics.

**Histopathology** 2024; 85(5): 701-715; Impact Factor=4.1; Impact Factor 2024=4.1; Typ=Journal Article;Review;

Fichtner A, **Nettersheim D**, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567832

Exposure of Bladder Cancer Cells to Blue Light ( $\lambda = 453 \text{ nm}$ ) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.

**Int J Mol Sci** 2024; 25(9): ; Impact Factor=4.9; Impact Factor 2024=4.9; Typ=Journal Article; Sturm S, **Niegisch G**, Windolf J, Suschek CV

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567539

New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.

**J Cell Mol Med** 2024; 28(9): ; Impact Factor=4.2; Impact Factor 2024=4.2; Typ=Journal Article;Research Support, Non-U.S. Gov't;

**Meneceur S, De Vos CE**, Petzsch P, Köhrer K, **Niegisch G, Hoffmann MJ**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 578032

The New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.

**J Cell Mol Med** 2024; 28(24): ; Impact Factor=4.2; Impact Factor 2024=4.2; Typ=Journal Article;

Weiten R, Engler T, Schorle H, Ellinger J, Saponaro M, Alajati A, **Nettersheim D**, Syring-Schmandke I

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569549

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

**J Clin Oncol** 2024; 42(20): 2446-2455; Impact Factor=43.4; Impact Factor 2024=43.4; Typ=Journal Article;Multicenter Study;

Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, **Niegisch G, Grunewald CM**, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 566905

Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.

**J Med Econ** 2024; 27(1): 531-542; Impact Factor=3.0; Impact Factor 2024=3.0; Typ=Meta-Analysis;Journal Article;

**Niegisch G**, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Deiters B, Maywald U, Wilke T,

Kearney M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571332

Prostate Cancer Screening in Young Men.

**J Pers Med** 2024; 14(8): ; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;Review;  
De Vrieze M, **Al-Monajjed R**, Boschheidgen M, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 565637

Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.

**J Urol** 2024; 211(3): 426-435; Impact Factor=7.5; Impact Factor 2024=7.5; Typ=Review;Journal Article;  
Nestler T, Paffenholz P, Pfister D, Schoch J, Nini A, **Hiester A**, **Albers P**, Heidenreich A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 565630

Reply by Authors.

**J Urol** 2024; 211(3): 435-435; Impact Factor=7.5; Impact Factor 2024=7.5; Typ=Journal Article;  
Nestler T, Paffenholz P, Pfister D, Schoch J, Nini A, **Hiester A**, **Albers P**, Heidenreich A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567850

Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.

**JAMA Oncol** 2024; 10(6): 755-764; Impact Factor=20.1; Impact Factor 2024=20.1; Typ=Journal Article;Clinical Trial, Phase II;Multicenter Study;

Grimm MO, Schostak M, Grün CB, Loidl W, Pichler M, Zimmermann U, Schmitz-Dräger B, Steiner T, Roghmann F, **Niegisch G**, Bolenz C, Schmitz M, Baretton G, Leucht K, Schumacher U, Foller S, Zengerling F, Meran J, TITAN-TCC Study Group

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 568896

Molecular and epigenetic ex vivo profiling of testis cancer-associated fibroblasts and their interaction with germ cell tumor cells and macrophages.

**Matrix Biol** 2024; 132(): 10-23; Impact Factor=4.8; Impact Factor 2024=4.8; Typ=Journal Article;

**Stephan A**, **Suhrmann JH**, **Skowron MA**, **Che Y**, Poschmann G, Petzsch P, Kresbach C, Wruck W, **Pongratanakul P**, Adjaye J, Stühler K, Köhler K, Schüller U, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 602125

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

**N Engl J Med** 2024; 391(8): 710-721; Impact Factor=78.5; Impact Factor 2024=78.5; Typ=Journal Article;Clinical Trial, Phase III;Multicenter Study;Randomized Controlled Trial;Comparative Study;

Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B, **LITESPARK-005**

**Investigators**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 565607

Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.

**N Engl J Med** 2024; 390(10): 944-946; Impact Factor=78.5; Impact Factor 2024=78.5; Typ=Editorial;

**Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564273

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

**N Engl J Med** 2024; 390(10): 875-888; Impact Factor=78.5; Impact Factor 2024=78.5; Typ=Clinical Trial, Phase III;Comparative Study;Journal Article;Multicenter Study;Randomized Controlled Trial;

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS, **EV-302 Trial Investigators**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 564159

Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany.

**Oncology Research and Treatment** 2024; 47(6): 296-305; Impact Factor=1.7; Impact Factor 2024=1.7; Typ=Journal Article;Review;Practice Guideline;

Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR, Birkner T, Büntzel J, Ebert M, Fasching P, Fischbach W, Fokas E, Fricke B, Hense H, Grohmann E, Hofheinz RD, Hüppe D, Huster S, Jahn P, Klinkhammer-Schalke M, Knauf W, Kraeft AL, Oliver Maier B, Marckmann G, **Niegisch G**, Otto L, Pelzer U, Piso P, Rosenau H, Schmitt J, Schoffer O, Sehouli J, Tannapfel A, Wedding U, Wesselmann S, Winkler EC, Zimmermann T, Wörmann B, Reinacher-Schick A, Schildmann J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569155

Treatment of uro-oncology patients. Urology update 2024

**Onkologie (Heidelberg, Germany)** 2024; 30(9): 857-862; Impact Factor=0.2; Impact Factor 2024=0.2; Typ=Article;

**Busshoff I, Huebner A, Vermeulen M, Wallisch M, Grunewald CM, Rehlinghaus M, Al-Monajjed R, Lakes J, Che Y, Radtke JP, Niegisch G**

Medline-ID fehlt, Web of Science-ID (ISI-LOC) vorhanden

ID: 568064

[Prostate cancer screening-current overview].

**Radiologie (Heidelb)** 2024; 64(6): 479-487; Impact Factor=0.6; Impact Factor 2024=0.6; Typ=Journal Article;Review;English Abstract;

**De Vrieze M, Hübner A, Al-Monajjed R, Albers P, Radtke JP, Schimmöller L, Boschheidgen M**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569538

Value of magnetic resonance angiography before prostatic artery embolization for intervention planning.

**Sci Rep** 2024; 14(1): ; Impact Factor=3.9; Impact Factor 2024=3.9; Typ=Journal Article;

Boschheidgen M, Ullrich T, **Al-Monajjed R**, Ziayee F, **Michalski R**, Steuwe A, Minko P, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 574853

PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled

trial.

**Trials** 2024; 25(1): ; Impact Factor=2.0; Impact Factor 2024=2.0; Typ=Journal Article;Clinical Trial Protocol;

**Al-Monajjed R, Albers P, Droop J**, Fugmann D, Noldus J, Palisaar RJ, Ritter M, Ellinger J, Krausewitz P, Truß M, Hadaschik B, Grünwald V, Schrader AJ, Papavassilis P, Ernstmann N, Schellenberger B, Moritz A, Kowalski C, Hellmich M, Heiden P, Hagemeyer A, Horenkamp-Sonntag D, Giessing M, Pauler L, Dieng S, Peters M, Feick G, Karger A, PRO-P study group  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 568908

Bladder preservation in adult patients with muscle-invasive bladder cancer (MIBC) who are not candidates for or refuse radical cystectomy

**Urologie** 2024; 63(4): 424-425; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=News Item; Rexer H, **Niegisch G**, Merseburger A

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 570331

[Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone].

**Urologie** 2024; 63(10): 985-993; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=English Abstract;Journal Article;Review;

Hausmann J, **Grunewald CM**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 574565

[Current developments in urothelial carcinoma].

**Urologie** 2024; 63(10): 975-976; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=Editorial;Introductory Journal Article;Journal Article;

**Niegisch G**, Kramer M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569533

[ERSPC trial-prostate-specific antigen (PSA)-based prostate cancer screening in older men].

**Urologie** 2024; 63(11): 1155-1157; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=Journal Article;

**Radtke JP**, Handke AE, **Haidl F**, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571005

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

**Urologie** 2024; 63(10): 1019-1027; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=English Abstract;Journal Article;Review;Consensus Development Conference;

**Niegisch G**, Bolenz C, Doehn C, Gakis G, Hartmann A, Müller-Huesmann H, Reis H, Roghmann F, Schwamborn K, Tiemann K, Retz M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 567562

[Multicenter networks, innovative concepts, and basic research-the mixture is important: report from the 14th symposium of the German Research Group on Bladder Cancer (DFBK) in Cologne].

**Urologie** 2024; 63(7): 702-704; Impact Factor=0.4; Impact Factor 2024=0.4; Typ=Congress;Journal Article;

Ecke TH, Wirtz RM, Heidenreich A, Füssel S, **Hoffmann MJ**, Gaisa NT, Nawroth R  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 545375

Molecular and histopathological characterization of seminoma patients with highly elevated human chorionic gonadotropin levels in the serum.

**Virchows Arch** 2024; 485(1): 123-130; Impact Factor=3.1; Impact Factor 2024=3.1; Typ=Journal Article;  
Seidel C, Paulsen FO, Nestler T, Cathomas R, Hentrich M, Paffenholz P, Bokemeyer C, Heidenreich A,  
**Nettersheim D**, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 569385

Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection.

**World J Surg Oncol** 2024; 22(1): ; Impact Factor=2.5; Impact Factor 2024=2.5; Typ=Journal Article;  
**Che Y, Wöltjen C, Lusch A, Winter C**, Trainer S, Schirren M, Sponholz S, Knoefel WT, **Albers P**,  
**Hiester A**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 571970

Bicenter validation of a risk model for the preoperative prediction of extraprostatic extension of localized prostate cancer combining clinical and multiparametric MRI parameters.

**World J Urol** 2024; 42(1): ; Impact Factor=2.9; Impact Factor 2024=2.9; Typ=Journal Article;Validation Study;Multicenter Study;

Ostau NEV, Handke AE, Wiesenfarth M, **Albers P**, Antoch G, Noldus J, Reis H, Cotarelo C, Preetz J, Umutlu L, Ingenwerth M, **Radtke JP**, Hadaschik B, Schimmöller L, Kesch C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

